Navigation Links
Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
Date:1/5/2009

SAN CARLOS, Calif., Jan. 5 /PRNewswire-FirstCall/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 27th Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel on Tuesday, January 13, 2009 at 10:00 a.m. Pacific time (1:00 p.m. Eastern time).

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until February 15, 2009.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its advanced polymer conjugate technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own high-value therapeutics that addresses unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. For more information on Nektar Therapeutics, please visit http://www.nektar.com.

     Nektar Contacts:
     Jennifer Ruddock
     Nektar Therapeutics
     650-631-4954
     jruddock@nektar.com

     Susan Noonan
     The SAN Group
     212-966-3650
     susan@sanoonan.com

'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
2. Nektar Therapeutics to Webcast R&D Day on November 12th
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
6. Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets
7. Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
8. Nektars PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress
9. Nektar Receives Patent Covering Pulmonary Targeted Antibiotics
10. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
11. West Concludes Agreement with Nektar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Kathy Goin is joining ... She brings years of expertise in establishing and leading clinical operations at Sponsors ... licensed occupational therapist, through a variety of leadership roles in Clinical Operations, to ...
(Date:5/22/2017)... , ... May 22, 2017 , ... ... with other leaders of the Maryland Biohealth community in developing and issuing recommendations ... Top 3 U.S. BioHealth Innovation Hub by 2023. , The ...
(Date:5/19/2017)... ... May 19, 2017 , ... The University City Science Center ... ripe for commercialization, and who are affiliated with the 21 partner academic and ... QED, now in its tenth round, is the first multi-institutional proof-of-concept program for ...
(Date:5/18/2017)... ... 17, 2017 , ... DAACRO ... power by providing investigators access to a high-profile scientific advisory board. Today, ... advisory board. “We are committed to offering superior services and solutions for ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
Breaking Biology News(10 mins):